Results 1 to 10 of about 515,934 (157)

Isolation and characterization of Brochothrix phage ADU4

open access: yesVirus Research, 2022
B. thermosphacta is a psychrotrophic bacterium that often forms the predominant part of the spoilage microflora of aerobically and anaerobically stored meats.
Abdulkerim Karaynir   +4 more
doaj   +1 more source

Highly Expressed Soluble Recombinant Anti-GFP VHHs in Escherichia coli via Optimized Signal Peptides, Strains, and Inducers

open access: yesFrontiers in Molecular Biosciences, 2022
Antigen-binding variable domains of the H chain of heavy-chain antibodies (VHHs), also known as nanobodies (Nbs), are of great interest in imaging technique, disease prevention, diagnosis, and therapy.
Shuangying Chao   +18 more
doaj   +1 more source

Triple-negative breast cancer: understanding Wnt signaling in drug resistance

open access: yesCancer Cell International, 2021
Triple-negative breast cancer (TNBC) is not as prevalent as hormone receptor or HER2-positive breast cancers and all receptor tests come back negative.
Parnaz Merikhian   +2 more
doaj   +1 more source

Stabilizing and Anti-Repressor Elements Effectively Increases Transgene Expression in Transfected CHO Cells

open access: yesFrontiers in Bioengineering and Biotechnology, 2022
Chinese hamster ovary (CHO) cells are currently the most widely used host cells for recombinant therapeutic protein (RTP) production. Currently, the RTP yields need to increase further to meet the market needs and reduce costs.
Qin Li   +8 more
doaj   +1 more source

Progress of Transposon Vector System for Production of Recombinant Therapeutic Proteins in Mammalian Cells

open access: yesFrontiers in Bioengineering and Biotechnology, 2022
In recent years, mammalian cells have become the primary host cells for the production of recombinant therapeutic proteins (RTPs). Despite that the expression of RTPs in mammalian cells can be improved by directly optimizing or engineering the expression
Mian Wei   +4 more
doaj   +1 more source

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy

open access: yesMolecular Therapy: Oncolytics, 2023
CD47 and its receptor signal regulatory protein α (SIRPα) act as a dominant antiphagocytic, “don’t eat me” signal. Recent studies reveal CD24 as a novel target for cancer immunotherapy by macrophages in ovarian cancer and breast cancer.
Yun Yang   +10 more
doaj   +1 more source

Factors Affecting the Expression of Recombinant Protein and Improvement Strategies in Chinese Hamster Ovary Cells

open access: yesFrontiers in Bioengineering and Biotechnology, 2022
Recombinant therapeutic proteins (RTPs) are important parts of biopharmaceuticals. Chinese hamster ovary cells (CHO) have become the main cell hosts for the production of most RTPs approved for marketing because of their high-density suspension growth ...
Zheng-Mei Li   +7 more
doaj   +1 more source

Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B [PDF]

open access: yes, 2012
Background: We have previously reported that human recombinant granzyme B (grB) mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a perforin-independent ...
AL Rerole   +50 more
core   +17 more sources

Advances of Glycometabolism Engineering in Chinese Hamster Ovary Cells

open access: yesFrontiers in Bioengineering and Biotechnology, 2021
As the most widely used mammalian cell line, Chinese hamster ovary (CHO) cells can express various recombinant proteins with a post translational modification pattern similar to that of the proteins from human cells.
Huan-Yu Zhang   +5 more
doaj   +1 more source

Serum-Free Medium for Recombinant Protein Expression in Chinese Hamster Ovary Cells

open access: yesFrontiers in Bioengineering and Biotechnology, 2021
At present, nearly 70% of recombinant therapeutic proteins (RTPs) are produced by Chinese hamster ovary (CHO) cells, and serum-free medium (SFM) is necessary for their culture to produce RTPs.
Weifeng Li   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy